Ovarian Neoplasms

• 

  Subject Areas on Research

  • 211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y. 
  • A Bayesian hierarchical approach for combining case-control and prospective studies. 
  • A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. 
  • A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. 
  • A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. 
  • A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer. 
  • A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. 
  • A branching process model of ovarian cancer. 
  • A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. 
  • A comparison of least squares and conditional maximum likelihood estimators under volume endpoint censoring in tumor growth experiments. 
  • A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. 
  • A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. 
  • A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. 
  • A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. 
  • A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. 
  • A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. 
  • A latent model for prioritization of SNPs for functional studies. 
  • A model to predict risk of blood transfusion after gynecologic surgery. 
  • A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). 
  • A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. 
  • A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer. 
  • A new index of priority symptoms in advanced ovarian cancer. 
  • A penalized likelihood approach for investigating gene-drug interactions in pharmacogenetic studies. 
  • A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. 
  • A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. 
  • A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. 
  • A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. 
  • A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). 
  • A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. 
  • A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. 
  • A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. 
  • A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. 
  • A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. 
  • A review of cost-effectiveness studies in ovarian cancer. 
  • A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. 
  • A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. 
  • A targeted genetic association study of epithelial ovarian cancer susceptibility. 
  • ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. 
  • ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. 
  • ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. 
  • ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. 
  • ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. 
  • ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. 
  • Abdominal pain and a pelvic mass. 
  • Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. 
  • Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. 
  • Acquisition of a side population fraction augments malignant phenotype in ovarian cancer. 
  • Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. 
  • Acute leukemia in Burkitt lymphoma. 
  • Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. 
  • Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer. 
  • Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation. 
  • Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging. 
  • Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging. 
  • Adnexal masses: MR imaging observations at 1.5 T, with US and CT correlation. 
  • Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. 
  • Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. 
  • Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. 
  • Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. 
  • Age at diagnosis and multiple primary cancers of the breast and ovary. 
  • Age at natural menopause and the risk of epithelial ovarian cancer. 
  • Allele loss on chromosome 1p36 in epithelial ovarian cancers. 
  • Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors. 
  • An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. 
  • An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. 
  • An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene. 
  • An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. 
  • Analgesic drug use and risk of ovarian cancer. 
  • Analgesic medication use and risk of epithelial ovarian cancer in African American women. 
  • Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. 
  • Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. 
  • Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. 
  • Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women. 
  • Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. 
  • Antiangiogenic therapies in epithelial ovarian cancer. 
  • Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer. 
  • Antidepressant medication use [corrected] and risk of ovarian cancer. 
  • Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. 
  • Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. 
  • Are Videos or Text Better for Describing Attributes in Stated-Preference Surveys? 
  • Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells. 
  • Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. 
  • Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. 
  • Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. 
  • Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). 
  • Assessment of hepatocyte growth factor in ovarian cancer mortality. 
  • Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. 
  • Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. 
  • Association Between Breastfeeding and Ovarian Cancer Risk. 
  • Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. 
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. 
  • Association between Body Powder Use and Ovarian Cancer: The African American Cancer Epidemiology Study (AACES). 
  • Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. 
  • Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer. 
  • Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. 
  • Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. 
  • Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. 
  • Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. 
  • Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study. 
  • Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. 
  • Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. 
  • Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. 
  • Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. 
  • Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. 
  • Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels. 
  • Availability of healthcare resources and epithelial ovarian cancer stage of diagnosis and mortality among Blacks and Whites. 
  • BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. 
  • BAX-mediated cell death affects early germ cell loss and incidence of testicular teratomas in Dnd1(Ter/Ter) mice. 
  • BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION: A CASE REPORT. 
  • BRAF polymorphisms and the risk of ovarian cancer of low malignant potential. 
  • BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. 
  • BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. 
  • BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis. 
  • BRCA1 mutations in primary breast and ovarian carcinomas. 
  • BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. 
  • BRCA2 monoclonal antibodies react with differentiating epithelium. 
  • BRCA2 mutations in primary breast and ovarian cancers. 
  • BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. 
  • Bayesian joint analysis of heterogeneous genomics data. 
  • Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. 
  • Biomarkers in the ovary. 
  • Breast and ovarian cancer in the older woman. 
  • Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. 
  • Breast carcinoma masquerading as primary ovarian neoplasm. 
  • CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. 
  • CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. 
  • CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift? 
  • COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies. 
  • Cabozantinib in ovarian clear cell cancers: UnMET expectations. 
  • Can we maximize both value and quality in gynecologic cancer care? A work in progress. 
  • Cancer recurrence and hyperglycemia with dexamethasone for postoperative nausea and vomiting prophylaxis: more moot points? 
  • Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. 
  • Carcinoid metastatic to the ovary. A clinocopathologic analysis of 35 cases. 
  • Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES). 
  • Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. 
  • Cell growth regulation in epithelial ovarian cancer. 
  • Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. 
  • Characterization of BRCA1 and BRCA2 mutations in a large United States sample. 
  • Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. 
  • Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. 
  • Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. 
  • Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. 
  • Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. 
  • Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists. 
  • Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. 
  • Chemotherapy-induced apoptosis in epithelial ovarian cancers. 
  • Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. 
  • Cigarette smoking and epithelial ovarian cancer by histologic type. 
  • Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. 
  • Cigarette smoking and the association with serous ovarian cancer in African American women: African American Cancer Epidemiology Study (AACES). 
  • Cigarette smoking and the risk of female reproductive cancer. 
  • Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. 
  • Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. 
  • Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. 
  • Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. 
  • Clear-cell adenocarcinoma of the vagina and cervix in young females: analysis of 37 tumors that persisted or recurred after primary therapy. 
  • Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. 
  • Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. 
  • Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. 
  • Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. 
  • Coexistence of a chemotactic factor and a retroviral P15E-related chemotaxis inhibitor in human tumor cell culture supernatants. 
  • Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. 
  • Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study. 
  • Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. 
  • Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. 
  • Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. 
  • Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. 
  • Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions. 
  • Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. 
  • Common variants at 19p13 are associated with susceptibility to ovarian cancer. 
  • Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. 
  • Common variation in Nemo-like kinase is associated with risk of ovarian cancer. 
  • Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. 
  • Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. 
  • Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. 
  • Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. 
  • Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study. 
  • Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. 
  • Comprehensive molecular portraits of human breast tumours. 
  • Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. 
  • Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. 
  • Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO. 
  • Consortium analysis of 7 candidate SNPs for ovarian cancer. 
  • Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. 
  • Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. 
  • Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. 
  • Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens. 
  • Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer. 
  • Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. 
  • Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer. 
  • Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. 
  • Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. 
  • Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. 
  • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. 
  • Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery. 
  • Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. 
  • Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. 
  • Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer. 
  • Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. 
  • Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. 
  • Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 
  • Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. 
  • Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. 
  • Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. 
  • Cyclin E overexpression relates to ovarian cancer histology but not to risk factors. 
  • Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and ovarian cancer risk: a meta-analysis. 
  • Cytologic studies of glucose-6-phosphate dehydrogenase in malignancy. 
  • DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. 
  • DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. 
  • Dairy, calcium, vitamin D and ovarian cancer risk in African-American women. 
  • Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. 
  • Death-associated protein kinase 1 promotes growth of p53-mutant cancers. 
  • Delayed treatment of papillary thyroid carcinoma arising from struma ovarii in a patient with history of bilateral salpingo-oophorectomy: a case report. 
  • Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes. 
  • Desmoplastic small round cell tumor masquerading as advanced ovarian cancer. 
  • Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test. 
  • Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. 
  • Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. 
  • Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. 
  • Development of a multimarker assay for early detection of ovarian cancer. 
  • Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. 
  • Dietary Quality and Ovarian Cancer Risk in African-American Women. 
  • Dietary carbohydrate intake, glycaemic load, glycaemic index and ovarian cancer risk in African-American women. 
  • Dietary inflammatory index and risk of epithelial ovarian cancer in African American women. 
  • Differential expression of immune related genes in high-grade ovarian serous carcinoma. 
  • Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. 
  • Differential platelet levels affect response to taxane-based therapy in ovarian cancer. 
  • Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. 
  • Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. 
  • Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. 
  • Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin. 
  • Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. 
  • ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. 
  • Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. 
  • Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment. 
  • Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer. 
  • Effect of Cultural, Folk, and Religious Beliefs and Practices on Delays in Diagnosis of Ovarian Cancer in African American Women. 
  • Effect of carbon dioxide on human ovarian carcinoma cell growth. 
  • Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? 
  • Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. 
  • Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. 
  • Elevated serum CA-125 levels: hepatitis or ascites? 
  • Elevation of multiple serum markers in patients with stage I ovarian cancer. 
  • End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. 
  • Endocervical-like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation. 
  • Endogenous RGS proteins attenuate Galpha(i)-mediated lysophosphatidic acid signaling pathways in ovarian cancer cells. 
  • Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. 
  • Enhanced uptake of a thermally responsive polypeptide by tumor cells in response to its hyperthermia-mediated phase transition. 
  • Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. 
  • Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. 
  • Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. 
  • Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. 
  • Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. 
  • Epigenetic determinants of ovarian clear cell carcinoma biology. 
  • Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. 
  • Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. 
  • Epithelial ovarian cancer risk among women with polycystic ovary syndrome. 
  • Epithelial ovarian cancer. 
  • Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. 
  • Erythropoietin Stimulates Tumor Growth via EphB4. 
  • Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. 
  • Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). 
  • Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach. 
  • Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored. 
  • Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. 
  • Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. 
  • European American stratification in ovarian cancer case control data: the utility of genome-wide data for inferring ancestry. 
  • Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. 
  • Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. 
  • Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. 
  • Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". 
  • Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. 
  • Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures. 
  • Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. 
  • Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. 
  • Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen. 
  • Evidence of a genetic link between endometriosis and ovarian cancer. 
  • Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. 
  • Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. 
  • Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. 
  • Expression signatures of TP53 mutations in serous ovarian cancers. 
  • FDG-PET for management of cervical and ovarian cancer. 
  • FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. 
  • Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2. 
  • Familial ovarian cancer: a population-based case-control study. 
  • Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death. 
  • Fertility drugs and ovarian cancer risk: a critical review of the literature. 
  • Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. 
  • Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. 
  • Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. 
  • First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. 
  • Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. 
  • Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. 
  • Frequency of germline and somatic BRCA1 mutations in ovarian cancer. 
  • Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. 
  • Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. 
  • Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. 
  • Functional Annotation Signatures of Disease Susceptibility Loci Improve SNP Association Analysis 
  • Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. 
  • Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support. 
  • GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. 
  • Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. 
  • Gene expression patterns that characterize advanced stage serous ovarian cancers. 
  • Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. 
  • Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. 
  • Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival. 
  • Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. 
  • Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations. 
  • Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? 
  • Genetic instability of microsatellites in endometrial carcinoma. 
  • Genetic susceptibility testing and prophylactic oophorectomy. 
  • Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore. 
  • Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. 
  • Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. 
  • Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. 
  • Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. 
  • Genetic/familial high-risk assessment: breast and ovarian. 
  • Genetic/familial high-risk assessment: breast and ovarian. 
  • Genetically predicted circulating protein biomarkers and ovarian cancer risk. 
  • Genetics and women's health issues--the commitment of EMS to women scientists and gender-associated disease topics. 
  • Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. 
  • Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. 
  • Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. 
  • Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. 
  • Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. 
  • Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women. 
  • Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. 
  • Genome-wide significant risk associations for mucinous ovarian carcinoma. 
  • Genomic sweeping for hypermethylated genes. 
  • Genomic tests for ovarian cancer detection and management. 
  • Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. 
  • Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. 
  • Global ovarian cancer health disparities. 
  • Glutathione S-transferase M1, T1, and P1 polymorphisms and ovarian cancer risk: a meta-analysis. 
  • Goblet-cell mucinous epithelium lining the endometrium and endocervix: evidence of metastasis from an appendiceal primary tumor through the use of cytokeratin-7 and -20 immunostains. 
  • Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. 
  • Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. 
  • Growth regulation and transformation of ovarian epithelium. 
  • HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. 
  • Ha-ras polymorphisms in epithelial ovarian cancer. 
  • Health economics of screening for gynaecological cancers. 
  • Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial. 
  • Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. 
  • Hepatoid yolk sac tumor of the ovary (endodermal sinus tumor with hepatoid differentiation): a light microscopic, ultrastructural and immunohistochemical study of seven cases. 
  • Heterogeneity of antigen expression in advanced epithelial ovarian cancer. 
  • High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. 
  • High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. 
  • High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. 
  • High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer. 
  • High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. 
  • High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results. 
  • High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. 
  • High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors. 
  • High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. 
  • History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. 
  • History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. 
  • History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. 
  • Histotype classification of ovarian carcinoma: A comparison of approaches. 
  • Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. 
  • Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium. 
  • Human ovarian cancer of the surface epithelium. 
  • Human ovarian cancers express somatostatin receptors. 
  • Hydrops fetalis associated with idiopathic arterial calcification. 
  • Hypertensive reactions associated with paclitaxel. 
  • Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. 
  • Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. 
  • IL-6 and ovarian cancer--letter. 
  • ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. 
  • Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. 
  • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 
  • Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. 
  • Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. 
  • Identification of six new susceptibility loci for invasive epithelial ovarian cancer. 
  • Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark? 
  • Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. 
  • Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis. 
  • Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. 
  • Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. 
  • Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers. 
  • Impact of hysterectomy and bilateral oophorectomy prevalence on rates of cervical, uterine, and ovarian cancer among American Indian and Alaska Native women, 1999-2004. 
  • Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. 
  • Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. 
  • Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery. 
  • Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention. 
  • In reply. 
  • In vitro fertilization and embryo transfer (IVF/ET): an established and successful therapy for endometriosis. 
  • Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer. 
  • Increased levels of laminin in ascitic fluid of patients with ovarian cancer. 
  • Increased risk for familial ovarian cancer among Jewish women: a population-based case-control study. 
  • Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. 
  • Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. 
  • Individual, Social, and Societal Correlates of Health-Related Quality of Life Among African American Survivors of Ovarian Cancer: Results from the African American Cancer Epidemiology Study. 
  • Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. 
  • Inherited determinants of ovarian cancer survival. 
  • Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. 
  • Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. 
  • Inherited variants in regulatory T cell genes and outcome of ovarian cancer. 
  • Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. 
  • Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists. 
  • Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. 
  • Insular carcinoid of ovary associated with malignant mucinous tumors. 
  • Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. 
  • Insurance coverage among women diagnosed with a gynecologic malignancy before and after implementation of the Affordable Care Act. 
  • Integrated genomic analyses of ovarian carcinoma. 
  • Integrated genomic characterization of endometrial carcinoma. 
  • Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. 
  • Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance. 
  • Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. 
  • Interphase fluorescence in situ hybridization for trisomy 12 on archival ovarian sex cord-stromal tumors. 
  • Intestinal obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival. 
  • Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. 
  • Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. 
  • Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. 
  • Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. 
  • Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. 
  • Is There a Role for Ovarian Cancer Screening in High-Risk Women? 
  • Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. 
  • Is stromal microinvasion in primary mucinous ovarian tumors with "mucin granuloma" true invasion? 
  • K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary. 
  • Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancer. 
  • LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. 
  • Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative. 
  • Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. 
  • Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. 
  • Letter: Treatment of dysgerminoma. 
  • Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women. 
  • Lipomatous uterine masses: potential to mimic ovarian dermoids on endovaginal sonography. 
  • Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. 
  • Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center. 
  • Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. 
  • Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. 
  • Loss of betaglycan expression in ovarian cancer: role in motility and invasion. 
  • Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. 
  • Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. 
  • Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer. 
  • Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. 
  • Lymph node sampling in patients with epithelial ovarian carcinoma. 
  • Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases. 
  • MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. 
  • MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. 
  • Main principles and outcomes of DNA methylation analysis. 
  • Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All? 
  • Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time? 
  • Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. 
  • Malignant struma ovarii: a blinded study of 86 cases assessing which histologic features correlate with aggressive clinical behavior. 
  • Malignant struma ovarii: a population-level analysis of a large series of 68 patients. 
  • Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. 
  • Malignant transformation of ovarian epithelium. 
  • Management of adnexal mass. 
  • Management of incidental ovarian tumors in patients undergoing gastric bypass. 
  • Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. 
  • Managing hereditary ovarian cancer risk. 
  • Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. 
  • Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. 
  • Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. 
  • Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. 
  • Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. 
  • Menopausal hormones and risk of ovarian cancer. 
  • Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium. 
  • Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. 
  • Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. 
  • Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies. 
  • Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. 
  • MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. 
  • MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. 
  • Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. 
  • Microarray analysis of gene expression in gynecologic cancers--still only the beginning. 
  • Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. 
  • Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity. 
  • Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. 
  • Mitochondrial Superoxide Dismutase Has a Protumorigenic Role in Ovarian Clear Cell Carcinoma. 
  • Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. 
  • Molecular approaches to prevention and detection of epithelial ovarian cancer. 
  • Molecular aspects of ovarian cancer. 
  • Molecular genetic features of ovarian cancer. 
  • Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors. 
  • Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. 
  • Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. 
  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. 
  • Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. 
  • Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. 
  • Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers. 
  • Mutations of the E-cadherin gene in human gynecologic cancers. 
  • Mycobacterium bovis peritonitis mimicking ovarian cancer in a young woman. 
  • NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. 
  • NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. 
  • Natural history of biologically malignant struma ovarii: analysis of 27 cases with extraovarian spread. 
  • Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. 
  • Neurohormonal peptides in ovarian carcinoids: an immunohistochemical study of 81 primary carcinoids and of intraovarian metastases from six mid-gut carcinoids. 
  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. 
  • No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. 
  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 
  • No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. 
  • Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. 
  • Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells. 
  • Notch3 pathway alterations in ovarian cancer. 
  • OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. 
  • OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. 
  • Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. 
  • Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. 
  • Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer. 
  • Obesity, weight gain, and ovarian cancer risk in African American women. 
  • Obesity: Too big a problem to ignore. 
  • Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy. 
  • Obstetrics and Gynecology Residents Can Accurately Classify Benign Ovarian Tumors Using the International Ovarian Tumor Analysis Rules. 
  • Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies. 
  • Omental cakes in American Burkitt lymphoma. Computed tomography demonstration. 
  • Oncogenes in ovarian cancer. 
  • Oncogenic pathway signatures in human cancers as a guide to targeted therapies. 
  • Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. 
  • Oral contraceptive pills. Prevention of ovarian cancer and other benefits. 
  • Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. 
  • Oral contraceptive use and risk of cancer--response. 
  • Oral contraceptive use for the primary prevention of ovarian cancer. 
  • Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. 
  • Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. 
  • Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women. 
  • Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. 
  • Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management. 
  • Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. 
  • Ovarian cancer epidemiology in the era of collaborative team science. 
  • Ovarian cancer risk associated with inherited inflammation-related variants. 
  • Ovarian cancer risk factors in African-American and white women. 
  • Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium. 
  • Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. 
  • Ovarian cancer, version 2.2013. 
  • Ovarian cancer, version 3.2012. 
  • Ovarian cancer. Clinical practice guidelines in oncology. 
  • Ovarian cancer: time to move beyond one size fits all. 
  • Ovarian teratoma with glial implants on the peritoneum. An analysis of 12 cases. 
  • Overexpression and mutation of p53 in epithelial ovarian cancer. 
  • Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. 
  • Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. 
  • Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. 
  • Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). 
  • PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. 
  • Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. 
  • Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience. 
  • Pathogenesis of ovarian cancers. 
  • Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. 
  • Pathology of epithelial ovarian tumors. 
  • Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach. 
  • Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: a type 2 hybrid controlled implementation-effectiveness trial. 
  • Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. 
  • Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. 
  • Patient preferences in advanced or recurrent ovarian cancer. 
  • Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. 
  • Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. 
  • Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. 
  • Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study. 
  • Performance of amplified DNA in an Illumina GoldenGate BeadArray assay. 
  • Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. 
  • Peritoneal carcinomatosis: preoperative CT with intraperitoneal contrast material. 
  • Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. 
  • Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. 
  • Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. 
  • Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. 
  • Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. 
  • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. 
  • Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. 
  • Phosphorus-based SAHA analogues as histone deacetylase inhibitors. 
  • Ploidy analysis of epithelial ovarian cancers using image cytometry. 
  • Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. 
  • Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. 
  • Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. 
  • Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. 
  • Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. 
  • Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer. 
  • Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. 
  • Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. 
  • Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women. 
  • Pooling of case specimens to create standard serum sets for screening cancer biomarkers. 
  • Population distribution of lifetime risk of ovarian cancer in the United States. 
  • Potential of CT-scan based tumor volume as a response indicator in chemotherapy of advanced epithelial ovarian cancer. 
  • Potentially functional variants in nucleotide excision repair pathway genes predict platinum treatment response of Chinese ovarian cancer patients. 
  • Pre-counseling education materials for BRCA testing: does tailoring make a difference? 
  • Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study. 
  • Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome. 
  • Prediagnostic Proinflammatory Dietary Potential Is Associated with All-Cause Mortality among African-American Women with High-Grade Serous Ovarian Carcinoma. 
  • Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals. 
  • Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model. 
  • Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. 
  • Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. 
  • Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 
  • Predictors of clinical outcomes in the laparoscopic management of adnexal masses. 
  • Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. 
  • Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. 
  • Pregnancy recency and risk of ovarian cancer. 
  • Premenopausal Hysterectomy and Risk of Ovarian Cancer in African-American Women. 
  • Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. 
  • Primary chemotherapy in epithelial ovarian cancer. 
  • Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? 
  • Primary peritoneal and ovarian cancers: an epidemiological comparative analysis. 
  • Primary trabecular carcinoid of the ovary. 
  • Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. 
  • Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. 
  • Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. 
  • Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. 
  • Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. 
  • Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. 
  • Prognostic gene expression signature for high-grade serous ovarian cancer. 
  • Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. 
  • Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. 
  • Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis. 
  • Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. 
  • Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin. 
  • Prostaglandin F2alpha levels in human ovarian plasma in pregnancy and in a case of Halban's disease. 
  • Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. 
  • Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. 
  • Quality of life in ICON7: need for patients' perspectives. 
  • Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. 
  • Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. 
  • Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. 
  • Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. 
  • Racial/ethnic disparities in ovarian cancer research. 
  • Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. 
  • Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. 
  • Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. 
  • Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. 
  • Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. 
  • Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients. 
  • Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. 
  • Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. 
  • Recombinant polyclonal antibody libraries. 
  • Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. 
  • Recreational physical activity and ovarian cancer risk and survival. 
  • Recreational physical activity and ovarian cancer risk in African American women. 
  • Recreational physical activity and survival in African-American women with ovarian cancer. 
  • Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. 
  • Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? 
  • Reduction of ovarian and oviductal cancers in calorie-restricted laying chickens. 
  • Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. 
  • Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. 
  • Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. 
  • Regulator of G-protein signalling expression and function in ovarian cancer cell lines. 
  • Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. 
  • Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. 
  • Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. 
  • Relationship of epithelial ovarian cancer to other malignancies within families. 
  • Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''. 
  • Reproductive factors and ovarian cancer risk in African-American women. 
  • Rethinking ovarian cancer: recommendations for improving outcomes. 
  • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. 
  • Rigor in Quality Improvement Studies and the Role of Time-Series Methodologies. 
  • Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Risk of benign gynecologic tumors in relation to prenatal diethylstilbestrol exposure. 
  • Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. 
  • Risk of ovarian cancer and inherited variants in relapse-associated genes. 
  • Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. 
  • Role of BRCA1 mutation screening in the management of familial ovarian cancer. 
  • Role of Increased n-acetylaspartate Levels in Cancer. 
  • Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. 
  • Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). 
  • Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. 
  • Role of eotaxin-1 signaling in ovarian cancer. 
  • Role of genetic polymorphisms and ovarian cancer susceptibility. 
  • Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium. 
  • Role of salpingectomy at the time of urogynecologic surgery. 
  • SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. 
  • SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. 
  • Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. 
  • Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer. 
  • Second-look operation for epithelial ovarian cancer: laparoscopy or laparotomy? 
  • Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. 
  • Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. 
  • Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. 
  • Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. 
  • Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. 
  • Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. 
  • Shared heritability and functional enrichment across six solid cancers. 
  • Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. 
  • Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer. 
  • Simultaneous endometrial malignant mixed mesodermal tumor and ovarian serous adenocarcinoma. 
  • Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. 
  • Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. 
  • Socioeconomic Status in Relation to the Risk of Ovarian Cancer in African-American Women: A Population-Based Case-Control Study. 
  • Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. 
  • Some mullerian inclusion cysts in lymph nodes may sometimes be metastases from serous borderline tumors of the ovary. 
  • Sonography of benign cystic teratoma of the ovary: pitfalls in diagnosis. 
  • Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. 
  • Specific keynote: genome copy number abnormalities in ovarian cancer. 
  • Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. 
  • Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. 
  • Stem-cell transplantation for the treatment of advanced solid tumors. 
  • Steroid secretion and testosterone binding in a woman with an ovarian hilus cell tumor and thyrotoxicosis. 
  • Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. 
  • Stretching the surface epithelium. 
  • Strumal carcinoid of the ovary: an analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid. 
  • Supplemental Selenium May Decrease Ovarian Cancer Risk in African-American Women. 
  • Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. 
  • Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. 
  • Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. 
  • Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. 
  • Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer. 
  • Survival in women with ovarian cancer with and without microsatellite instability. 
  • Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. 
  • Synchronous occurrence of gastrointestinal stromal tumour and ovarian neoplasm in a patient presenting with acute cholecystitis. 
  • Synchronous primary carcinoma of breast and ovary versus ovarian metastases. 
  • Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. 
  • Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78. 
  • Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. 
  • Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. 
  • Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. 
  • Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). 
  • Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. 
  • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. 
  • Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. 
  • Targeting ovarian cancer-initiating cells. 
  • Targeting slow-proliferating ovarian cancer cells. 
  • Targeting the epigenome in ovarian cancer. 
  • Telomerase activity in human ovarian carcinoma. 
  • Testing for hereditary breast and ovarian cancer in the southeastern United States. 
  • The Association Between Body Mass Index and Presenting Symptoms in African American Women with Ovarian Cancer. 
  • The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-A potential therapeutic target. 
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. 
  • The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. 
  • The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). 
  • The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. 
  • The association between progesterone receptor expression and survival in women with adult granulosa cell tumors. 
  • The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. 
  • The biology of ovarian cancer. 
  • The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer. 
  • The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. 
  • The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists? 
  • The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. 
  • The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. 
  • The effectiveness of ovarian cancer screening. A decision analysis model. 
  • The genetic attributable risk of breast and ovarian cancer. 
  • The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases. 
  • The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. 
  • The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. 
  • The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. 
  • The prognostic significance of angiogenesis in epithelial ovarian carcinoma. 
  • The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. 
  • The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study. 
  • The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. 
  • The rise of genomic profiling in ovarian cancer. 
  • The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. 
  • The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. 
  • The role of peptide growth factors in epithelial ovarian cancer. 
  • The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. 
  • The steroid profile of a virilizing ovarian tumor. 
  • The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. 
  • Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. 
  • Thrombocytopenia in association with a wandering spleen. 
  • Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. 
  • Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer. 
  • Top 10 Tips Palliative Care Clinicians Should Know When Caring for Patients with Ovarian Cancer. 
  • Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. 
  • Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha. 
  • Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. 
  • Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. 
  • Transforming growth factor-beta differentially inhibits epithelial ovarian carcinoma cells from primary and metastatic isolates without up-regulation of p21WAF1. 
  • Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. 
  • Transhiatal esophagogastrectomy for an isolated ovarian cancer metastasis to the esophagus. 
  • Transperitoneal Versus Extraperitoneal Laparoscopic Lymphadenectomy for Gynecological Malignancies: A Systematic Review and Meta-analysis. 
  • Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. 
  • Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity. 
  • Tubal ligation and fatal ovarian cancer in a large prospective cohort study. 
  • Tubal ligation and ovarian cancer risk in African American women. 
  • Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. 
  • Tubal ligation, hysterectomy, and risk of ovarian cancer. 
  • Tubal ligation, hysterectomy, and risk of ovarian cancer. 
  • Tumor marker CA-125 as an evaluator and response indicator in ovarian cancer: its quantitative correlation with tumor volume. 
  • Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. 
  • Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. 
  • U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. 
  • Ultrastructure of primary and metastatic ovarian carcinoids: analysis of 11 cases. 
  • Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer. 
  • Unilateral luteoma of pregnancy mimicking a malignant ovarian mass on magnetic resonance and ultrasound. 
  • Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. 
  • Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism. 
  • Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. 
  • Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. 
  • Vacuum-assisted closure for cutaneous gastrointestinal fistula management. 
  • Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. 
  • Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. 
  • Validity of models for predicting BRCA1 and BRCA2 mutations. 
  • Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer. 
  • Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer. 
  • Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer. 
  • Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. 
  • Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. 
  • Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. 
  • Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. 
  • What Women and Their Physicians Need to Know About the UKCTOCS Study and Ovarian Cancer Screening. 
  • Whole-Genome and Segmental Homozygosity Confirm Errors in Meiosis as Etiology of Struma Ovarii. 
  • XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. 
  • Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk. 
  • Yin yang 1 modulates taxane response in epithelial ovarian cancer. 
  • [Expectations and defeat in the treatment of epithelial cancer of the ovary]. 
  • [Krukenberg tumor: a clinical case report]. 
  • p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. 
  • p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. 
  • p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases. 
  • p53-based gene therapy of ovarian cancer: magic bullet? 
  • rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Bradford, William Dalton, Professor of Pathology, Pathology
  • Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology